Devra Igra

VALFIX Medical is revolutionizing heart valve surgery with our ground-breaking, multi-wire technology. We are spearheading the development of a comprehensive transcatheter repair solution that offers a high-quality, minimally invasive alternative to traditional open-heart surgery. Harnessing innovation, our technology aims to eradicate mitral regurgitation (MR), a debilitating heart condition, in over 90% of severe MR patients. We are diligently working to provide a solution that mirrors the surgical standard in transcatheter mitral valve repair and replacement, but without the associated surgical risks. Mitral regurgitation affects millions worldwide, with a staggering 15 million patients globally. Of these, 4.5 million experience severe MR, yet only 2% of them have access to open heart surgery. The remaining 98% typically manage with medication, a solution that tragically sees nearly half of them pass away within two years. Given the constraints of existing treatments for MR patients with heart failure - the controversial nature of surgical repair and replacement and the limited effectiveness of new treatments - the need for our work at VALFIX Medical is more crucial than ever. At VALFIX Medical, we're not just creating products; we're crafting the future of heart health. To learn more about our transformative work, visit our website or reach out to our dedicated team.